Latest Us Market Entry News

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.

Ovanti Limited has completed a $1 million capital raise through a discounted share placement to accelerate its buy now, pay later business expansion in the United States.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Talga Group has opened a $5 million Share Purchase Plan at $0.41 per share, offering shareholders free attaching and piggyback options to support its planned anode production ramp-up and US expansion.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Jindalee Lithium has successfully raised $1.5 million through an oversubscribed Share Purchase Plan, exceeding its $1 million target to fund the McDermitt Lithium Project and a US SPAC transaction.